Last reviewed · How we verify
Mino-Lok
Mino-Lok is a antimicrobial lock solution that prevents biofilm formation and reduces bacterial colonization on central venous catheters.
Mino-Lok is a antimicrobial lock solution that prevents biofilm formation and reduces bacterial colonization on central venous catheters. Used for Prevention of catheter-related bloodstream infections (CRBSIs) in patients with central venous catheters.
At a glance
| Generic name | Mino-Lok |
|---|---|
| Also known as | Standard of care antibiotics + Mino-Lok |
| Sponsor | Leonard-Meron Biosciences, Inc. |
| Drug class | Antimicrobial catheter lock solution |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Hospital-Acquired Infection Prevention |
| Phase | Phase 3 |
Mechanism of action
Mino-Lok combines minocycline and edetic acid (EDTA) to create a catheter lock solution that inhibits bacterial adhesion and biofilm development on the internal surfaces of central venous catheters. The formulation is designed to be instilled into the catheter lumen between uses to prevent catheter-related bloodstream infections (CRBSIs) in patients requiring long-term venous access.
Approved indications
- Prevention of catheter-related bloodstream infections (CRBSIs) in patients with central venous catheters
Common side effects
- Local catheter site reactions
- Thrombosis
- Catheter dysfunction
Key clinical trials
- Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI (PHASE3)
- Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |